Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today ...
18h
Distinct metabolic signature found in patients with heart failure with preserved ejection fraction
What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...
U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in ...
Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice.
Recent data underscores the need for improved primary care detection of heart failure with preserved ejection fraction.
Exercise tolerance reflects the ability to sustain physical activity and is influenced by cardiovascular, pulmonary, and ...
aDepartment of Cardiovascular Sciences, University of Leicester, United Kingdom bNIHR Leicester Biomedical Research Centre –Cardiology, Department of Cardiovascular Sciences, College of Life Sciences, ...
A new study from Temple University and Cedars-Sinai has revealed that mitochondrial remodeling and metabolic disruptions are key contributors to heart failure with preserved ejection fraction (HFpEF).
Can weight loss reverse heart failure? A new study shows that heart muscle cells regain strength and muscle contractions ...
A new study suggests severe obesity may weaken heart muscle cells in people with heart failure with preserved ejection ...
A review indicates obesity may amplify pathophysiology in HFrEF rather than acting as a primary cause, though weight loss data remain inconclusive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results